請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33968
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王榮德 | |
dc.contributor.author | Jung-Nien Lai | en |
dc.contributor.author | 賴榮年 | zh_TW |
dc.date.accessioned | 2021-06-13T05:50:17Z | - |
dc.date.available | 2006-08-03 | |
dc.date.copyright | 2006-08-03 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-07 | |
dc.identifier.citation | 一、
1.World Health Organization: WHO Traditional Medicine Strategy 2002~2005. Geneva World Health Organization 2002. 2.婦科心法。In:弘晝、鄂爾泰、錢斗保、吉慶、普福、興貴。醫宗金鑑,台北,台灣,大中國圖書公司,1977;4:160。 3. 吳炫璋、賴榮年、葉家豪:台灣的中醫醫療政策。北市醫學雜誌,2005;2(10):866-879. 4. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. Geneva. 2000: 67. 5. Tseng WL. Frequency of Prescribing Aristolochic Acid-associated Chinese Herb Medicine in National Health Insurance in Taiwan, 1997-2001. Masters Thesis. Taipei: National Taiwan University, 2005. 6. Deeks AA, McCabe MP. Well-being and menopause: An investigation of purpose in life, self-acceptance and social role in premenopausal, perimenopausal and postmenopausal women. Qual Life Res 2004 Mar;13(2):389-398. 7. World Health Organization Scientific Group. Research on the menopause in the 1990s. WHO technical series report no. 866. Geneva, Switzerland: World Health Organization, 1996. 8. Fu SY, Anderson D, Courtney M. Cross-cultural menopausal experience: comparison of Australian and Taiwanese women. Nurs Health Sci 2003 Mar;5(1):77-84. 9. Ringa V. Menopause and treatments. Qual Life Res 2000;9:695-707. 10. Hardy R, Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med 2002;55(11):1975-1988. 11. Fuh JL, Wang SJ, Lu SR, Juang KD, Chiu LM. The Kinmen women health investigation: a menopausal study of a population aged 40-54. Maturitas 2001;39:117-124. 12. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy-a placebo-controlled study. Int J Fertil Menopausal Stud. 1995;40(2):73-78. 13. Wklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-830. 14. Lee I, Wang HH. Menopausal experiences and self-care behaviors among mid-life women. Nurs Res 2000;8:71-84. 15. 曹麗英、周碧琴、洪麗玲、張淑紅、高月梅、蕭冰如。更年期婦女自覺不確定及健康行為之探討。長庚護理 2002;13(3):228-239. 16. Bonomi AE, Patrick DL, Bushnell DM, Martin M. Quality of life measurement: will we ever be satisfied? Clin Epidemiol 2000;53(1):19-23. 17. 張玨、陳芬苓。女性更年期研究的回顧與展望。婦女與兩性學刊1993;4:263-294. 18. Chang C. Menopausal Women’s health is issue of public health policy. Taiwan J Public Health 2003;22(4):245-250. 19. The WHOQOL-Taiwan Group: The User’s Manual of the Development of the WHOQOL-BREF Taiwan Version. 1st rev. ed. Taiwan: Taipei, 2001. 20. Marciniak A, Niero M. Integrating the patient’s views into the measurement of quality of life: Examples from the peri- and post-menopausal periods. Qual Life Res 2000;9:775-784. 21. Shih YT, Chang HY, Le KH, Lin MC, Su WC: Introduction to the National Health Interview Survey (NHIS). NHIS Brief Communication No.1, June 2002. 22. Fuh JL, Wang SJ, Lu SR, Juang KD, Chiu LM: The Kinmen women-health investigation (KIWI): a menopausal study of a population aged 40-54. Maturitas 2001;39(2):117-124. 23. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric 2000;3(1):50-58. 24. Freeman EW, Sammel, Liu L, Martin P: Psychometric properties of a menopausal symptom list. Menopause. 2003 May-Jun;10(3):258-65. 25. Hunter MS. The Women's Health Questionnaire (WHQ): Frequently Asked Questions (FAQ). Health Qual Life Outcomes 2003;1(1):41. 26. Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13(2):299-310. 27. Freedman RR. Physiology of hot flashes. Am J Human Biol 2001;13(4):453-464. 28. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180(3 Pt 2):S312-316. 29. Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes: aetiology and management. Drugs Aging 2001;18(8):597-606. 30. Notelovitz M. Hot flashes and androgens: a biological rationale for clinical practice. Mayo Clin Proc 2004;79(4 Suppl):S8-13. 31. Sloan JA, Loprinzi CL, Novotny PJ et al. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290. 32. Alder E. The Blatt-Kupperman menopausal index: a critique. Maturitas 1998;29:19-24. 33. Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effect of tibolone on climacteric symptoms. Br J Obstet Gynaecol 2002;109:1109-1114. 34. Ringa V. Menopause and treatments. Quality of Life Research 2000;9:695-707. 35. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashed. J Clin Oncol 2002 Mar 15;20(6):1578-83. 36. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM Jr, Burnham NL. Transdernal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994 Jan;12(1):155-8. 37. Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288(3): 321-333. 38. Aldridge, D. 1989. A guide to preparing a research application. Comp. Med. Res 3(3):31-37. 39. Anthony, H.M. 1987. Some methodological problems in the assessment of complementary therapy. Stats. Med. 6:761-771. 40. World Health Organization Regional Offices for the Western Pacific. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. Malina. 1993. 41. World Health Organization Scientific Group. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products. WHO technical series report no. 850. Geneva, Switzerland: World Health Organization, 1996. 42. World Health Organization (WHO). General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. Geneva, Switzerland: World Health Organization, 2000. 43. Chen LC, Tsao YT, Yen KY, Chen YF, Chou MH, Lin MF. A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric symptoms. Maturitas 2003 30;44(1):55-62. 44. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003, 22(3): 61-76. 45. Buckwalter JA, Saltzman C, Brown T, Schurman DJ. The impact of osteoarthritis: implications for research. Clin Orthop 2004, 427 Suppl:S6-15. 46. Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med 2004, 164(12):1299-304. 47. Chard JA, Tallon D, Dieppe PA. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis 2000, 59(6):414-8. 48. Chard J, Dieppe P. The case for nonpharmacologic therapy of osteoarthritis. Curr Rheumatol Rep 2001, 3(3):251-7. 49. Gidwani S, Fairbank A. The orthopaedic approach to managing osteoarthritis of the knee.BMJ 2004, 329(7476):1220-4. 50. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 2004, 51(5):746-54. 51. Zochling J, March L, Lapsley H, Cross M, Tribe K, Brooks P. Use of complementary medicines for osteoarthritis--a prospective study. Ann Rheum Dis 2004, 63(5):549-54. 52. Berman BM, Singh BB, Lao L, Langenberg P, Li H, Hadhazy V, et al. A randomized trial of acupuncture as an adjunctive therapy in osteoarthritis of the knee. Rheumatology (Oxford) 1999, 38(4):346-54. 53. Vas J, Mendez C, Perea-Milla E, Vega E, Panadero MD, Leon JM, et al. Acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee: randomised controlled trial. BMJ 2004, 329(7476):1216. 54. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology (Oxford) 2001, 40(7):779-93. 55. Michalsen A, Moebus S, Spahn G, Esch T, Langhorst J, Dobos GJ. Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study. Altern Ther Health Med 2002, 8(5):84-8. 56. Guillemin F, Virion JM, Escudier P, De Talance N, Weryha G. Effect on osteoarthritis of spa therapy at Bourbonne-les-Bains. Joint Bone Spine 2001, 68(6):499-503. 57. Guillemin F, Virion JM, Escudier P, De Talance N, Weryha G. Effect on osteoarthritis of spa therapy at Bourbonne-les-Bains. Joint Bone Spine 2001, 68(6):499-503. 58. National Palace Museum, Taipei. Invaluable Prescriptions for Ready Reference. Online document at: www.npm.gov.tw/exh92/medicinal9207/english/content/m4.htm Accessed April 16, 2006. 66. Eisenberg DM, Davis RB, Ettner SL, Apple S, Wilkey S, Rompay MV and Kessler RC: Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280:1569-1575. 67. Eisenberg DM, Kessler RC, Foster C. et al: Unconventional medicine in the United States: Prevalence, costs, and patterns of use. New England Journal of Medicine 1993;328:246-252. 59. Eisenberg DM, Davis RB, Ettner SL, Apple S, Wilkey S, Rompay MV and Kessler RC: Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280:1569-1575. 60. Eisenberg DM, Kessler RC, Foster C. et al: Unconventional medicine in the United States: Prevalence, costs, and patterns of use. New England Journal of Medicine 1993;328:246-252. 61.賴榮年、呂庶熙、吳炫璋、葉家豪:實證醫學運用於台灣針灸醫學之初探。中華針灸醫學會雜誌,2004;7:43-52. 62. 吳炫璋、賴榮年、葉家豪:台灣的中醫醫療政策。北市醫學雜誌,2005;2(10):866-879. 63. Chuang CH, Lai JN, Wang JD, Chang PJ, Chen PC. Prevalence and related factors of Chinese herbal medicine use in pregnant women of Taipei, 1985-1987. Taiwan J Public Health 2005;24(4):335-347. 64. Chuang CH, Lai JN, Wang JD, Chang PJ, Chen PC. Use of Coptidis Rhizoma and foetal growth: a follow-up study of 9895 pregnancies. Pharmacoepidemiol Drug Saf. 2006;15(3):185-92. 65. Chuang CH, Doyle P, Wang JD, Chang PJ, Lai JN, Chen PC. Herbal medicines used during the first trimester and major congenital malformations : an analysis of data from a pregnancy cohort study. Drug Saf. 2006;29(6):537-548. 66. 葉家豪、卓雨青、賴榮年、施至玲、呂庶熙:退化性膝關節炎之針灸療法初探。中華針灸醫學會雜誌,2005;7:37-47. 67. Fry, E.N. Acupressure and postoperative vomiting. Anaesthesia 1986;41(6): 661–662. 68. Dundee, J.W., R.G. Ghaly, K.M. Bill, W.N. Chestnutt, K.T.J. Fitzpatrick and A.G.A. Lynas. Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting. Br. J. Anaesth. 1989;63(5): 612–618. 69. 賴榮年:2005 國際中醫藥實證醫學研討會(International Society for Chinese Medicine)—台灣推展中醫實證醫學借鏡。北市醫學雜誌,2005;2(7):676-684. 二、 1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–8 2. Deeks AA, McCabe MP. Well-being and menopause: an investigation of purpose in life, selfacceptance and social role in pre-menopausal, peri-menopausal and post-menopausal women. Qual Life Res 2004;13:389–98 3. Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;88:1516–22 4. Dennerstein L, Lehert P, Guthrie J. The effects of the menopausal transition and biopsychosocial factors on well-being. Arch Women Ment Health 2002;5:15–22 5. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345–56 6. Pan HA, Wu MH, Hsu CC, Yao BL, Huang KE. The perception of menopause among women in Taiwan. Maturitas 2002;41:269–74 7. Tsao LI. Relieving discomforts: the help-seeking experiences of Chinese perimenopausal women in Taiwan. J Adv Nurs 2002;39:580–8 8. Bonomi AE, Patrick DL, Bushnell DM, Martin M. Quality of life measurement: will we ever be satisfied? J ClinEpidemiol 2000;53:19–23 9. Hunt SM. The subjective health of older women: measuring outcomes in relation to prevention. Qual Life Res 2000;9:709–19 10. Marciniak A, Niero M. Integrating the patient’s views into the measurement of quality of life: examples from the peri- and post-menopausal periods. Qual Life Res 2000;9:775–84 11. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric 2000;3:50–8 12. Hilditch JR, Lewis J, Peter A, et al. A menopausespecific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161–75 13. Wool C, Cerutti R, Marquis P, Cialdella P, Hervie C, ISGQL. Italian Study Group on Quality of Life. Psychometric validation of two Italian quality of life questionnaires in menopausal women. Maturitas 2000;35:129–42 14. WHOQOL Group. Development of the WHOQOL: rationale and current status. Int J Mental Health 1994;23:24–56 15. Skevington SM, Lotfy M, O’Connell KA, WHOQOL Group. The World Health Organization’sWHOQOL- BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299–310 16. The WHOQOL-Taiwan Group. Introduction to the development of the WHOQOL-Taiwan version. Taiwan J Public Health 2000;19:315–24 17. Hsiung PC, Fang CT, Chang YY, Chen MY, Wang JD. Comparison of WHOQOL-BREF and SF-36 in patients with HIV infection. Qual Life Res 2005;14:141–50 18. Lai JN. Quality of life as defined by menopausal women use a qualitative approach. Master Thesis. Taipei: National Taiwan University, 2001 19. Shih YT, Hung YT, Chang HY, et al. The design, contents, operation and the characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. Taiwan J Public Health 2003;22:419–30 20. Lin TH, Chang HY, Weng WS, et al. TheNational Health Interview Survey information system: an overview. Taiwan J PublicHealth 2003;22:431–40 21. The WHOQOL-Taiwan Group. The User’s Manual of the Development of the WHOQOLBREF Taiwan Version, 1st edn. Taipei: WHOQOL-Taiwan Group, 2001 22. Lin MR, Yao KP, Hwang JS, Wang JD. Scale descriptor selection for Taiwan-version of questionnaire of World Health Organization quality of life. Chinese J Public Health 1999;18:262–70 23. Yao G, Chung CW, Yu CF, Wang JD. Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc 2002;101:342–51 24. Yao G, Wu CH. Factorial invariance of the WHOQOL-BREF among disease groups. Qual Life Res 2005;13:933–46 25. Avis NE, Assmann SF, Kravitz HM, Ganz PA, Ory M. Quality of life in diverse groups of midlife women: assessing the influence of menopause, health status and psychosocial and demographic factors. Qual Life Res 2004;13:933–46 26. Lai JN, Hwang JS, Chen HJ, Wang JD. Finished herbal product as an alternative treatment for menopausal symptoms in climacteric women. J Altern Complement Med 2005;11:1075–84 27. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebocontrolled study. Menopause 2003;10:29–36 28. Kok L, Kreijkamp-Kaspers S, Grobbee DE, Lampe JW, van der Schouw YT. A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women. Menopause 2005; 12:56–62 29. Shulman LP, Harari D. Low-dose transdermal estradiol for symptomatic perimenopause. Menopause 2004;11:34–9 30. Casper RF, Dodin S, Reid RL, et al. The effect of 20 mg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997;4:139–47 31. Chang C, Chen FL, Hu YH. Women’s attitudes toward the menopause. Taiwan J Public Health 1993;12:239–60 32. Wu YH, Lu PC. The research on the poverty of elderly women – the factors of the poverty and major hardships. Master Thesis. Taipei: National Chengchi University, 1997 33. Women’s Welfare System. The Report on Women’s Status in Taiwan [serial online]. 1997 Mar [cited 2005 Oct 10];1(1):[9 screens]. Available from: URL: http://taiwan.yam.org.tw/womenweb/st/98e/e_status.htm 34. Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff Millwood) 2003;22:61–76 35. Horng C, Huarng F. TQM adoption by hospital in Taiwan. TQM Magazine 2002;13:441–63 36. Stooler MK. The socio-economics of insomnia: the materials and methods. Eur Psychiatry 1997;12:41–8 37. Regestein QR, Friebely J, Shifren JL, et al. Selfreported sleep in postmenopausal women. Menopause 2004;11:198–207 38. Ledesert B, Ringa V, Breart G. Menopause and perceived health status among the women of the French GAZEL cohort. Maturitas 1994;20: 113–20 39. Ohayon MM, Hong SC. Prevalence of insomnia and associated factors in South Korea. J Psychosom Res 2002;53:593–600 40. Kawada T, Yosiaki S, Yasuo K, Suzuki S. Population study on the prevalence of insomnia and insomnia-related factors among Japanese women. Sleep Med 2003;4:563–7 41. Mitchell ES, Woods NF. Symptom experiences of midlife women: observations from the Seattle midlife women’s health study. Maturitas 1996;25:1-10. 三、 1. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103–115. 2. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression:Results from the Massachusetts Women’s Health Study. Ann Epidemiol 1994;4:213–220. 3. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–358. 4. Jaszmann L, van Lith ND, Zaat JCA. The perimenopausal symptoms: The statistical a nalysis of a survey. Med Gynaecol Sociol 1969;4:268–727. 5. Kronenberg F. Hot flashes: Epidemiology and physiology. Ann N Y Acad Sci 1 990;592:52–86. 6. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;30:1062–1071. 7. Prior JC. Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397–428. 8. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025–4030. 9. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: A cross-sectional study of a population based sample. J Clin Endocrinol Metab 1995;80: 3537–3545. 10. Pan HA, Wu MH, Hsu CC, et al. The perception of menopause among women in Taiwan. Maturitas 2002;41:269–274. 11. Kaunitz AM. Oral contraceptive use in perimenopause. Am JObstet Gynecol 2001;185(Suppl):S32–S37. 12. North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589–600. 13. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591–597. 14. Gelfand MM, Moreau M, Ayotte NJ, et al. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: A placebo-controlled study. Menopause 2003; 10:29–36. 15. Hersch AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: Annual trends and responses to recent evidence. JAMA 2004;291:47–53. 16. Miller HG, Li RM. Measuring hot flashes: Summary of a National Institutes of Health workshop. Mayo Clin Proc 2004; 79:777–781. 17. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987;156:561–565. 18. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial. Lancet 2000;356:2059–2063. 19. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578–1583. 20. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA 2003;289:2827–2834. 21. Horst DW, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. J Affect Disord 1998;51:237–254. 22. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Patho-physiology and treatment of hot flashes. Mayo Clin Proc 2002; 77:1207–1218. 23. Walter FM, Emery JD, Rogers M, Britten N. Women’s views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy. Patient Educ Couns 2004;53:121–128. 24. Chou P. Factors related to utilization of traditional Chinese medicine in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 2001;64:191–202. 25. Wu AC, Hu YH. Many ways to health: A study of 2,000 rural and urban Taiwan families. Am J Chin Med 1980;8:313–330. 26. Angell M, Kassirer JP. Alternative medicine—the risks of untested and unregulated remedies. NEJM 1998;33:839–841. 27. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States—prevalence, costs, and patterns of use. NEMJ 1993;328:246–252. 28. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003;10:465–476. 29. The Committee on Chinese Medicine and Pharmacy. The standardized formulas announced by Health Department in Taiwan. Online document at: www.ccmp.gov.tw/index-c/1.htm Accessed March 31, 2005. 30. Kupperman KI, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13:688–703. 31. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: A double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824–830. 32. Fang CT, Hsiung PC, Yu CF, et al. Validation of the World Health Organization Quality of Life instrument in patients with HIV infection. Qual Life Res 2002;11:753–762. 33. O’Carroll RE, Smith K, Couston M, et al. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res 2000; 9:121–124. 34. Skevington SM, Lotfy M, O’Connell KA; WHOQOL Group. The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299–310. 35. Wang J-D. Basic Principles and Practical Applications in Epidemiological Research. River Edge, NJ: World Scientific, 2002;4:57–77. 36. North American Menopause Society. Treatment of menopauseassociated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause 2004;11:11–33. 37. Haines CJ, Yim SF, Chung TK, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas 2003;44:207–214. 38. Matikainen T, Ding YQ, Vergara M, et al. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol Metab 1992;75:820–825. 39. Vihtamaki T, Simoni M, Tuimala R, et al. Self-adjusted postmenopausal hormone replacement therapy: Effects on the biological and immunological profile of FSH and correlation to climacteric symptoms. Eur J Endocrinol 2002;146:333–338. 40. Kok L, Kreijkamp-Kaspers S, Grobbee DE, et al. A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women. Menopause 2005;12:56–62. 41. Shulman LP, Harari D. Low-dose transdermal estradiol for symptomatic perimenopause. Menopause 2004;11:34–39. 42. Casper RF, Dodin S, Reid RL, et al. The effect of 20 g ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997;4:139–147. 43. Randolph JF, Jr., Sowers MF, Gold EB, et al. Reproductive hormones in the early menopausal transition: Relationship to ethnicity, body size, and menopausal status J Clin Endocrinol Metab 2003;88:1516–1522. 44. Kasuga M, Makita K, Ishitani K, et al. Relation between climacteric symptoms and ovarian hypofunction in middle-aged and older Japanese women. Menopause 2004;11:631–638. 四、 1. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350: 503-508. 2. Felson DT. The epidemiology of knee osteoarthritis: Results from the Framingham osteoarthritis study. Semin Arthritis Rheum 1990; 20(3 suppl 1): 42-50 3. Hernandez-Diaz S, Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160(14): 2093-2099. 4. National Palace Museum, Taipei. Invaluable Prescriptions for Ready Reference. Online document at: www.npm.gov.tw/exh92/medicinal9207/english/content/m4.htm Accessed April 16, 2006. 5. Committee on Chinese Medicine and Pharmacy. The standardized formulae announced by the Health Department in Taiwan. Online document at: www.ccmp.gov.tw/ index-c/1.htm Accessed March 31, 2005. 6. Cosyns JP. Aristolochic acid and ‘Chinese herbs nephropathy’: A review of the evidence to date. Drug Saf 2003; 26(1): 33-48. 7. US Food and Drug Administration. Letter to industry associations regarding safety concerns related to the use of botanical products containing Aristolochic acid; 9 April 2001. Online document at: www.cfsan.fda.gov/~dms/ds-botl4.html Accessed April 30, 2006. 8. Health Canada advises consumers not to use products containing Aristolochic acid Ottawa: Health Canada; 26 July 2004. Online document at: www.hc-sc.gc.ca/ahc-asc/ media/advisories-avis/2004/2004_43_e.html Accessed April 30, 2006. 9. Drew AK, Whyte IM, Bensoussan A, et al. Chinese herbal medicine toxicology database: monograph on Herba Asari, ‘Xi Xin’. J Toxicol Clin Toxicol 2002; 40(2): 169-172. 10. Huang CY, Tseng MC, Lin JH. Analyzing Aristolochic acids in Chinese herbal preparations using LC/MS/MS. J Food Drug Anal 2005; 13(2): 125-131. 11. McConnell S, Kolopack P, Davis AM. The Western Otario and McMaster Universities Osteoarthritis Index (WOMAC): A review of its utility and measurement properties. Arthritis Care Res 2001; 45: 453-461. 12. Yao G, Chung CW, Yu CF, Wang JD. Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc 2002; 101:342-51. 13. Angst F, Stucki G, Aeschlimann A. Quality of life assessment in osteoarthritis. Expert Rev Pharmacoeconomics Outcome Res 2003; 3: 623-636. 14. Arden N, Nevitt MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol 2006; 20(1): 3-25. 15. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. Geneva. 2000: 67. 16. Tseng WL. Frequency of Prescribing Aristolochic Acid-associated Chinese Herb Medicine in National Health Insurance in Taiwan, 1997-2001. Masters Thesis. Taipei: National Taiwan University, 2005. 17. Teekachunhatean S, Kunanusorn P, Rojanasthien N, et al. Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. BMC Complement Altern Med 2004; 4(1): 19-27. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33968 | - |
dc.description.abstract | 本計劃之目標為由台大公共衛生學院成立監測中心,採多中心主動監測系統追蹤、監測下,探討台更一號治療更年期症候群及獨活寄生湯之臨床療效與安全性。中藥複方台更一號研究的主要療效指標為Kupperman index score第0、4週與12週追蹤評估量表之分數變化,次要指標為世界衛生組織生活品質量表台灣簡明版( WHOQOL-BREF Taiwan version )在第0、4週與12週之分數變化;獨活寄生湯研究的主要療效指標為Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)及疼痛視覺評估量表,第0、2週與4週追蹤評估量表之分數變化,次要指標為WHOQOL-BREF Taiwan version 及中醫證型問卷在第0、2週與4週之分數變化。至於安全性的評估上,則主動觀察受試個案在研究期間所出現的不良事件,並進一步評估不良事件與研究藥物間的因果關係。
中藥複方台更一號研究依個案納入/排除條件共收納143位受試者,共126位受試者進入試驗的藥物擴清期 (0-2週),並接受用藥前的臨床評估(基礎值,含身體檢查、生命徵象、Kupperman index、WHOQOL-BREF Taiwan version、實驗室數值檢測等),之後則開始服用12週的研究藥物,每天三次,每次4公克;期間亦分別於服藥後的1、2、3、4、6、8、10、12 週回診,最後共有103位受試者完成期末評估。獨活寄生湯研究依個案納入/排除條件共收納69位受試者,共69位受試者進入試驗的藥物擴清期 (0-2週),並接受用藥前的臨床評估(基礎值,含身體檢查、生命徵象、WOMAC index、WHOQOL-BREF Taiwan version、實驗室數值檢測等),之後則開始服用4週的研究藥物,每天二次,每次2.5公克;期間亦分別於服藥後的2、4 週回診,最後共有68受試者完成期末評估。每位受試者皆充分了解本研究之目的及內容,簽署知情同意書後,並於每次回診接受各項療效與安全性指標的評值,由各參與醫院之專職研究護士,依研究標準作業流程 (Standard Operation Procedure),執行主動之監測。 中藥複方台更一號研究以12週追蹤之103位更年期婦女而言,更年期症候群及生活品質分數有進步。主要指標 Kupperman index score其4週與12週追蹤的前後差異性有統計上顯著之差異。次要指標WHOQOL-BREF Taiwan version其12週追蹤的前後差異性不顯著。以4週追蹤之68退化性膝關節病人而言,膝關節疼痛、僵硬及功能分數在獨活寄生湯治療2與4週後有統計上顯著之改善。然而傳統辨別獨活寄生湯適用的症狀及證型如腰膝痠軟及畏惡風寒,及次要指標WHOQOL-BREF Taiwan version其2與4週追蹤的前後差異性不顯著。在安全性上,中藥複方台更一號其所發生的不良反應嚴重度多屬於輕微至中度,僅有5件顯示與研究藥物具「極有可能」的相關性-分別是噁心 (1件),腹瀉 (2件),胃悶脹痛 (1件)及腹脹 (1件),且並不影響受試者生活功能。獨活寄生湯的不良反應亦僅有4件顯示與研究藥物具「極有可能」的相關性-分別是心悸、皮膚白斑、臉潮紅及腹瀉各1件。研究結果顯示:台更1號在治療更年期症候群上,獨活寄生湯在治療退化性膝關節上,除了具有不錯的療效外,亦相當的安全。 總而言之,採主動監測系統的追蹤觀察研究法,可清楚的釐清台更1號及獨活寄生湯的藥物安全的因果關係,當然透過此研究法,我們驗證了台更1號及獨活寄生湯,分別在更年期症候群及退化性膝關節上,可能有效的適應症及群族,提供了古籍未曾記載的實證資料。 | zh_TW |
dc.description.abstract | Context: There is a paucity of data supporting the efficacy of herbal medicines in treating both menopausal symptoms and osteoarthritis in knee.
Objective: One is to evaluate safety and efficacy of the finished Chinese herbal product TMN-1 in the treatment of menopausal symptoms in climacteric women. Second is to evaluate both the safety and efficacy of the finished Chinese herbal product, DU-HUO-JI-SHENG-TANG, in reducing the symptoms of degenerative osteoarthritis (OA) of the knee. Design and Setting: Two prospective, observational follow-up studies were carried out. TMN-1 trial was conducted in 4 hospitals in Taiwan between July 2003 and December 2004. DHJST trial was conducted in two hospitals in Taipei between April and October 2005. Participants: TMN-1 trial : Initially 126 women were included who were between 45 and 55 years of age, were experiencing hot flashes, and were without hormone replacement therapy. Women were excluded if they had any signs of active cancer. Of the participants, 82% completed the study. The reasons for withdrawal included adverse effects (n = 7), failed to return (n = 7), lack of efficacy (n = 6), and from protocol deviation (n = 3). DHJST trial : Initially 87 subjects sought for medical help were screened. 69 of them were diagnosed as a degenerative OA of the knee through roentgenography diagnosed by radiologists. After the collection of baseline data, 1 of them failed to return for lack of efficacy, while the rest completed the study. Intervention: TMN-1 trial : Every participant received TMN-1 treatment 4 gm, 3 times per day, for 12 weeks. DHJST trial : Each of the sample participants received DU-HUO-JI-SHENG-TANG treatment at a rate of 2.5 gm, twice per day, for four weeks. Main Outcome Measure: TMN-1 trial : Primary measures were change in frequency of hot flashes and severity of menopausal symptoms measured by Kupperman Index (KI). Secondary outcomes included changes in quality of life and adverse events. DHJST trial : Baseline scores were measured on the Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), followed by further measures at the end of weeks 1, 2 and 4. The World Health Organization Quality of Life (WHOQOL) assessment was undertaken as a secondary outcome, with pattern identification (bian zheng) questionnaires being adopted and adverse events also being measured. Multivariate regression models were constructed to explore the differences between the WOMAC and WHOQOL scores at weeks 2 and 4, self-compared with the baseline by various determinants, including age, gender, body mass index, severity at baseline, use of rescue medication, aversion to cold and flaccidity of the lower back and knees. Results: TMN-1 trial : Significant improvement in scores of hot flashes and KI at weeks 4 and 12 in the 50 peri- and 53 postmenopausal women who completed this study (p<0.001). Logistic regression analyses showed that perimenopausal women with hot flashes had sevenfold (95% confidence interval [CI], 1.8 to 28.0) odds of improvement in favor of treatment, whereas that of the postmenopausal group was 1.5 (95% CI, 0.5 to 4.2). Further analyses showed that TMN-1 produced superior benefit in women with moderate and severe menopausal symptoms (KI >=21), compared with those with mild symptoms. It also improved symptoms of insomnia, nervousness, melancholia, and palpitation in perimenopausal women. Five adverse drug reactions were detected: three single events of nausea, abdominal pain, and abdominal fullness, and 2 events of diarrhea. DHJST trial : Amongst the 68 participants, there were statistically-significant reductions in WOMAC scores for pain, stiffness and physical functioning in the second and fourth weeks, with the effects first appearing during week 2. By week 4, the mean WOMAC scores had fallen from 22.2 to 16.1 for pain, from 28.1 to 18.5 for stiffness, and from 22.6 to 18.2 for physical functioning, whilst the global score for pain under the ‘visual analogue scale’ (VAS) was reduced from 38.7 to 27.8. The results indicate that the magnitudes of the reductions in the above symptoms were associated with the baseline severity of the symptoms. Contrary to the hypotheses proposed in an ancient text on traditional Chinese medicine, there were no significant effects on flaccidity of the lower back and knees, or aversion to cold. There was also no significant change in either the WHOQOL assessment or the pattern difference based upon traditional theory. There were only four adverse drug reactions judged to be potentially related to the treatment, involving single events of skin discoloration, flashes, diarrhea and tachycardia. Conclusion: TMN-1 trial : This study provides evidence that 12 weeks of TMN-1 therapy is a viable alternative treatment to consider in perimenopausal women with hot flashes, particularly in those with palpitation, emotional disturbance, and insomnia. DHJST trial : For degenerative OA of knee, four-week therapy with the Chinese herbal products DU-HUO-JI-SHENG-TANG seemed to be ineffective in treating flaccidity or aversion to cold, but appeared both to reduce pain and stiffness, and to improve physical function. In conclusion, observational studies have specific advantages in studying aspects of clinical safety. The use of such studies to prove efficacy is limited because bias in patient selection may occur. However, the results we found from this kind of studies can provide more precious information to verify whether it is a potential treatment or not to symptom relief during climacteric period or symptomatic knee in patients with OA. Nevertheless, the level of evidence on efficacy of both TMN-1 and DHJST can be significantly increased by well-designed double blind randomized studies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T05:50:17Z (GMT). No. of bitstreams: 1 ntu-95-D90841002-1.pdf: 1223747 bytes, checksum: 12eef1f5eba6efd616d3740b812c7f89 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 摘要....................................................6
第一章、總論...........................................12 (一)中藥臨床療效評估.................................12 (二)更年期與生活品質相關之研究.......................14 (三)更年期潮熱與治療相關之研究.......................16 (四)退化性膝關節炎與治療相關之研究...................18 (五)未來研究的建議...................................20 第二章、影響更年期婦女生活品質之預測因子...............28 第三章、治療更年期症候群之中藥複方療效及安全性主動監測研究.......51 第四章、獨活寄生湯治療退化性膝關節炎之療效及安全性主動監測研究.....78 | |
dc.language.iso | en | |
dc.title | 中藥台更一號及獨活寄生湯對更年期症候群及退化性膝關節炎的臨床療效評估 | zh_TW |
dc.title | Assessment of therapeutic effects of TMN-1 and DHJST on menopausal symptoms and osteoarthritis | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 林宜信,周松男,陳恆德,詹長權 | |
dc.subject.keyword | 中藥複方,更年期症候群,潮熱,退化性膝關節炎,主動安全監測,獨活寄生湯, | zh_TW |
dc.subject.keyword | Finished herb product,perimenopause,hot flashes,WHOQOL-BREF,Quality of life,degenerative knee osteoarthritis, DU-HUO-JI-SHENG-TANG,pattern identification,Western Ontario and McMaster Universities Osteoarthritis Index, | en |
dc.relation.page | 94 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-07 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 職業醫學與工業衛生研究所 | zh_TW |
顯示於系所單位: | 職業醫學與工業衛生研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.2 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。